Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis?

J Am Coll Cardiol. 2025 Jan 16:S0735-1097(24)10558-X. doi: 10.1016/j.jacc.2024.10.126. Online ahead of print.

Authors

Richard K Cheng¹, Douglas Leedy¹, Frederick L Ruberg²

Affiliations

¹ Division of Cardiology, University of Washington, Seattle, Washington, USA.
² Section of Cardiovascular Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, USA. Electronic address: frruberg@bu.edu.

PMID: 39846939
DOI: 10.1016/j.jacc.2024.10.126

No abstract available

Keywords: cardiac amyloid; transthyretin amyloid.

Publication types

Editorial